Johnson & Johnson Q4 EPS Meets Estimates, Guidance Up and Targets Raised to $265
Johnson & Johnson reported fourth-quarter EPS of $2.46 on $24.56 billion revenue, up 9.1% year-over-year, and set FY2026 guidance at $11.43 – $11.63 EPS while maintaining a $1.30 quarterly dividend. CHMP granted a positive opinion for AKEEGA in BRCA1/2-mutant prostate cancer and analysts raised price targets up to $265.
1. Institutional Investing Activity
In the third quarter, Banyan Capital Management Inc. initiated a new stake in Johnson & Johnson, purchasing 3,853 shares valued at approximately $714 000 and making JNJ its 22nd largest holding (0.3% of assets). This follows Norges Bank’s acquisition of a $4.88 billion position in the second quarter and Vanguard Group’s incremental 1.3% increase to 237.0 million shares (valued at $36.21 billion). Geode Capital Management and Legal & General also boosted their stakes by 2.1% and 6.2%, respectively, underscoring continued confidence from long-term institutional investors, who now own 69.55% of the outstanding shares.
2. Regulatory and Legal Developments
European regulator CHMP issued a positive opinion for AKEEGA (niraparib + abiraterone) in BRCA1/2-mutant metastatic hormone-sensitive prostate cancer, paving the way for a new oncology revenue stream. In the U.S., a federal judge dismissed a fraud lawsuit related to J&J’s talc bankruptcy strategy, eliminating one legal overhang. However, legal commentators caution broader talc litigation remains unresolved, while unusually high options volume suggests elevated trading interest and potential short-term volatility.
3. Q4 Earnings Performance and FY 2026 Guidance
On January 21 2026, JNJ reported Q4 revenue of $24.56 billion (up 9.1% year-over-year) and EPS of $2.46, in line with consensus. Net margin stood at 28.5% and return on equity at 33.3%. The company raised its full-year 2026 EPS guidance to a range of $11.43–$11.63. JNJ’s 50-day and 200-day moving averages are $210.72 and $191.57, respectively, against a 52-week trading range of $141.50 to $230.00 and a market capitalization of $547.2 billion.
4. Analyst Sentiment and Shareholder Returns
Following Q4 results, Daiwa Capital Markets and Scotiabank raised price targets to $237 and $265 with Outperform ratings, while Morgan Stanley upgraded based on stronger growth prospects. Consensus from 26 analysts remains a Moderate Buy with an average target of $233.05. The Board declared a $1.30 quarterly dividend (2.3% yield; payout ratio 47.1%) payable March 10 to holders of record February 24, extending JNJ’s dividend increase streak to 63 consecutive years.